| 摘要 |
Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing i nformation to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption i nclude a serum imiquimod concentrations of less than about 2 ng/mL, a decrea se in median white blood cell count by about 1.4*109/L or a decrease in medi an absolute neutrophil count by about 1.42*109/L Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves an d pressure- sensitive adhesive compositions to treat dermatological disorder s in children, namely, molluscum contagiosum, viral infections, such as Type 1 or Type Il Herpes simplex infections and condyloma acuminata, genital war ts and perianal warts, actinic keratosis and superficial basal cell carcinom a, and to induce interferon biosynthesis, are disclosed.
|
